Tevogen Bio Holdings Inc
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 pat… Read more
Tevogen Bio Holdings Inc (TVGN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.466x
Based on the latest financial reports, Tevogen Bio Holdings Inc (TVGN) has a cash flow conversion efficiency ratio of 0.466x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.65 Million) by net assets ($-7.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tevogen Bio Holdings Inc - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Tevogen Bio Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tevogen Bio Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tevogen Bio Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
|
-0.165x |
|
Mortgage Oil Corp
PINK:MGAG
|
0.601x |
|
CRUZ BATTERY METALS CORP.
F:BR00
|
N/A |
|
WITBE EO -53
F:2B2
|
N/A |
|
Delixy Holdings Limited Ordinary Shares
NASDAQ:DLXY
|
N/A |
|
Plus Tech Innovation PCL
BK:PTECH
|
-0.041x |
|
Trillion Energy International Inc.
OTCQB:TRLEF
|
-0.030x |
|
LakeShore Biopharma Co., Ltd
NASDAQ:LSB
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Tevogen Bio Holdings Inc (2022–2025)
The table below shows the annual cash flow conversion efficiency of Tevogen Bio Holdings Inc from 2022 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $-6.67 Million | $-12.00 Million | 1.798x | +1977.65% |
| 2024-06-30 | $-94.43 Million | $-8.17 Million | 0.087x | -66.06% |
| 2023-06-30 | $-33.95 Million | $-8.66 Million | 0.255x | -20.31% |
| 2022-06-30 | $-16.49 Million | $-5.27 Million | 0.320x | -- |